JP2000344773A - カルバペネム誘導体、およびその用途並びにその中間体化合物 - Google Patents

カルバペネム誘導体、およびその用途並びにその中間体化合物

Info

Publication number: JP2000344773A
Authority: JP; Japan
Prior art keywords: group; compound; carboxylate; hydroxyethyl; ylthio
Prior art date: 1998-07-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP10203730A

Other languages

English (en)

Japanese (ja)

Other versions

JP2000344773A5 (th

Inventor

Hiroshi Matsui

博松井

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Kyoto Pharmaceutical Industries Ltd

Original Assignee

Kyoto Pharmaceutical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-17

Filing date

1998-07-17

Publication date

2000-12-12

1998-07-17 Application filed by Kyoto Pharmaceutical Industries Ltd filed Critical Kyoto Pharmaceutical Industries Ltd

1998-07-17 Priority to JP10203730A priority Critical patent/JP2000344773A/ja

1999-04-28 Priority to IDW20002432A priority patent/ID27081A/id

1999-04-28 Priority to PCT/JP1999/002301 priority patent/WO1999057121A1/ja

1999-04-28 Priority to DE69932927T priority patent/DE69932927D1/de

1999-04-28 Priority to HU0101735A priority patent/HUP0101735A3/hu

1999-04-28 Priority to AU36272/99A priority patent/AU760386B2/en

1999-04-28 Priority to AT99918272T priority patent/ATE337321T1/de

1999-04-28 Priority to RU2000130224/04A priority patent/RU2222540C2/ru

1999-04-28 Priority to EP99918272A priority patent/EP1078927B1/en

1999-04-28 Priority to CA002330641A priority patent/CA2330641A1/en

1999-04-28 Priority to US09/674,363 priority patent/US6410525B1/en

1999-04-28 Priority to SK1638-2000A priority patent/SK16382000A3/sk

1999-04-28 Priority to TR2000/03199T priority patent/TR200003199T2/xx

1999-04-28 Priority to BR9910098-3A priority patent/BR9910098A/pt

1999-04-28 Priority to PL99343728A priority patent/PL343728A1/xx

1999-04-28 Priority to CZ20003954A priority patent/CZ292623B6/cs

1999-04-28 Priority to KR1020007012121A priority patent/KR100589030B1/ko

1999-04-28 Priority to CNB998080306A priority patent/CN1163494C/zh

1999-04-28 Priority to YU66700A priority patent/YU66700A/sh

1999-04-28 Priority to NZ508493A priority patent/NZ508493A/en

1999-04-29 Priority to TW088106898A priority patent/TW528750B/zh

1999-04-30 Priority to CO99026262A priority patent/CO5011051A1/es

1999-04-30 Priority to ARP990102033A priority patent/AR018335A1/es

2000-10-31 Priority to NO20005480A priority patent/NO20005480L/no

2000-11-29 Priority to BG105004A priority patent/BG105004A/xx

2000-12-12 Publication of JP2000344773A publication Critical patent/JP2000344773A/ja

2005-10-27 Publication of JP2000344773A5 publication Critical patent/JP2000344773A5/ja

Status Pending legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 63
YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical class C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 title description 6
-1 pivaloyloxymethyl Chemical group 0.000 claims abstract description 129
125000000217 alkyl group Chemical group 0.000 claims abstract description 19
125000004432 carbon atom Chemical group C* 0.000 claims description 9
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 7
239000003242 anti bacterial agent Substances 0.000 claims description 6
VANVCHUEALPLAG-FWPZAIACSA-N [(1R)-1-hydroxyethyl] (5S)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound C[C@H](O)OC(=O)C1=CC(C)[C@@H]2CC(=O)N12 VANVCHUEALPLAG-FWPZAIACSA-N 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 3
238000001727 in vivo Methods 0.000 claims description 3
238000006243 chemical reaction Methods 0.000 abstract description 24
230000000844 anti-bacterial effect Effects 0.000 abstract description 11
239000003814 drug Substances 0.000 abstract description 8
229940124597 therapeutic agent Drugs 0.000 abstract description 8
239000002904 solvent Substances 0.000 abstract description 6
210000001035 gastrointestinal tract Anatomy 0.000 abstract description 4
PELJISAVHGXLAL-UHFFFAOYSA-N iodomethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCI PELJISAVHGXLAL-UHFFFAOYSA-N 0.000 abstract description 4
125000005843 halogen group Chemical group 0.000 abstract description 2
229910052736 halogen Inorganic materials 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
230000004048 modification Effects 0.000 abstract 1
238000012986 modification Methods 0.000 abstract 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 43
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
238000005160 1H NMR spectroscopy Methods 0.000 description 13
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
239000002585 base Substances 0.000 description 8
239000000203 mixture Substances 0.000 description 8
238000010898 silica gel chromatography Methods 0.000 description 8
238000003756 stirring Methods 0.000 description 8
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
229910052739 hydrogen Inorganic materials 0.000 description 7
238000000034 method Methods 0.000 description 7
229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
235000017557 sodium bicarbonate Nutrition 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
239000000243 solution Substances 0.000 description 6
208000035473 Communicable disease Diseases 0.000 description 5
229910000027 potassium carbonate Inorganic materials 0.000 description 5
125000001424 substituent group Chemical group 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
150000007529 inorganic bases Chemical class 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
150000007530 organic bases Chemical class 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
230000035484 reaction time Effects 0.000 description 4
238000007086 side reaction Methods 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000011734 sodium Substances 0.000 description 4
208000035143 Bacterial infection Diseases 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
208000022362 bacterial infectious disease Diseases 0.000 description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
OKDMJXVHXRPNNZ-UHFFFAOYSA-N (4-nitrophenoxy)carbonyloxymethyl 2-methylpropanoate Chemical compound CC(C)C(=O)OCOC(=O)OC1=CC=C([N+]([O-])=O)C=C1 OKDMJXVHXRPNNZ-UHFFFAOYSA-N 0.000 description 2
125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000000654 additive Substances 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
159000000007 calcium salts Chemical class 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
238000011161 development Methods 0.000 description 2
125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
239000008187 granular material Substances 0.000 description 2
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
125000005244 neohexyl group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
150000003222 pyridines Chemical class 0.000 description 2
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
DYFCTJYNLSDCOG-UHFFFAOYSA-N (4-nitrophenoxy)carbonyloxymethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCOC(=O)OC1=CC=C([N+]([O-])=O)C=C1 DYFCTJYNLSDCOG-UHFFFAOYSA-N 0.000 description 1
BFKLBUHJBIEJDG-UHFFFAOYSA-N (4-nitrophenoxy)carbonyloxymethyl acetate Chemical compound CC(=O)OCOC(=O)OC1=CC=C([N+]([O-])=O)C=C1 BFKLBUHJBIEJDG-UHFFFAOYSA-N 0.000 description 1
QEXRDKAXGSPPMI-UHFFFAOYSA-N (4-nitrophenoxy)carbonyloxymethyl propanoate Chemical compound CCC(=O)OCOC(=O)OC1=CC=C([N+]([O-])=O)C=C1 QEXRDKAXGSPPMI-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010061695 Biliary tract infection Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
241000978776 Senegalia senegal Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
229940125716 antipyretic agent Drugs 0.000 description 1
125000004391 aryl sulfonyl group Chemical group 0.000 description 1
125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
208000003167 cholangitis Diseases 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
125000006165 cyclic alkyl group Chemical group 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
150000002960 penicillins Chemical class 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
125000005633 phthalidyl group Chemical group 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000000039 preparative column chromatography Methods 0.000 description 1
238000012746 preparative thin layer chromatography Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
125000006000 trichloroethyl group Chemical group 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
208000019206 urinary tract infection Diseases 0.000 description 1
125000005023 xylyl group Chemical group 0.000 description 1

Landscapes

Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP10203730A 1998-05-01 1998-07-17 カルバペネム誘導体、およびその用途並びにその中間体化合物 Pending JP2000344773A (ja)

Priority Applications (25)

Application Number	Priority Date	Filing Date	Title
JP10203730A JP2000344773A (ja)	1998-07-17	1998-07-17	カルバペネム誘導体、およびその用途並びにその中間体化合物
IDW20002432A ID27081A (id)	1998-05-01	1999-04-28	Senyawa-senyawa turunan karbapenem, penggunaan serta senyawa-senyawa intermedietnya
PCT/JP1999/002301 WO1999057121A1 (en)	1998-05-01	1999-04-28	Carbapenem derivatives, utilization thereof and intermediate compounds of the same
DE69932927T DE69932927D1 (de)	1998-05-01	1999-04-28	Cabapenemderivate, ihre anwendung und ihre zwischenprodukte
HU0101735A HUP0101735A3 (en)	1998-05-01	1999-04-28	Carbapenem derivatives, pharmaceutical compositions thereof and intermediate compounds
AU36272/99A AU760386B2 (en)	1998-05-01	1999-04-28	Carbapenem derivatives, utilization thereof and intermediate compounds of the same
AT99918272T ATE337321T1 (de)	1998-05-01	1999-04-28	Cabapenemderivate, ihre anwendung und ihre zwischenprodukte
RU2000130224/04A RU2222540C2 (ru)	1998-05-01	1999-04-28	Производные карбапенема, их применение и промежуточные соединения для их получения
EP99918272A EP1078927B1 (en)	1998-05-01	1999-04-28	Carbapenem derivatives, utilization thereof and intermediate compounds of the same
CA002330641A CA2330641A1 (en)	1998-05-01	1999-04-28	Carbapenem derivatives, utilization thereof and intermediate compounds of the same
US09/674,363 US6410525B1 (en)	1998-05-01	1999-04-28	Carbapenem derivatives, utilization thereof and intermediate compounds of the same
SK1638-2000A SK16382000A3 (sk)	1998-05-01	1999-04-28	Karbapénové deriváty, ich vyžitie a ich medziproduktové zlúčeniny
TR2000/03199T TR200003199T2 (tr)	1998-05-01	1999-04-28	Karbapenem türevleri, bunların kullanımı ve ara birleşiği
BR9910098-3A BR9910098A (pt)	1998-05-01	1999-04-28	Derivados de carbapenem, utilização dos mesmos e compostos intermediários dos mesmos
PL99343728A PL343728A1 (en)	1998-05-01	1999-04-28	Carbapenem derivatives, utilization thereof and intermediate compounds of the same
CZ20003954A CZ292623B6 (cs)	1998-05-01	1999-04-28	Karbapenemové deriváty, antibakteriální činidlo s jejich obsahem a jejich meziproduktové sloučeniny
KR1020007012121A KR100589030B1 (ko)	1998-05-01	1999-04-28	카르바페넴 유도체, 그 사용 방법 및 그 중간체 화합물
CNB998080306A CN1163494C (zh)	1998-05-01	1999-04-28	碳青霉烯衍生物、其用途及其中间体化合物
YU66700A YU66700A (sh)	1998-05-01	1999-04-28	Derivati karbapenema, njihovo korišćenje i intermedijarna jedinjenja istih
NZ508493A NZ508493A (en)	1998-05-01	1999-04-28	Carbapenem derivatives, utilization thereof and intermediate compounds of the same
TW088106898A TW528750B (en)	1998-05-01	1999-04-29	A carbapenem compound having an antibacterial activity and a pharmaceutical composition containing the same
CO99026262A CO5011051A1 (es)	1998-05-01	1999-04-30	Compuesto de carbapenem, uso del mismo y sus compuestos intermedios
ARP990102033A AR018335A1 (es)	1998-05-01	1999-04-30	Compuesto carbapenico, agente antibacteriano que lo comprende y compuesto carbapenico util como intermediario para la obtencion del primero
NO20005480A NO20005480L (no)	1998-05-01	2000-10-31	Carbapenemderivater, anvendelse derav samt mellomprodukt
BG105004A BG105004A (en)	1998-05-01	2000-11-29	Carbapenem derivatives, utilization thereof and intermediate compounds of the same

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP10203730A JP2000344773A (ja)	1998-07-17	1998-07-17	カルバペネム誘導体、およびその用途並びにその中間体化合物

Publications (2)

Publication Number	Publication Date
JP2000344773A true JP2000344773A (ja)	2000-12-12
JP2000344773A5 JP2000344773A5 (th)	2005-10-27

Family

ID=16478915

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP10203730A Pending JP2000344773A (ja)	1998-05-01	1998-07-17	カルバペネム誘導体、およびその用途並びにその中間体化合物

Country Status (1)

Country	Link
JP (1)	JP2000344773A (th)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2016517435A (ja) *	2013-03-15	2016-06-16	カラファーマシューティカルズインコーポレイテッド	メロペネム誘導体及びその使用

1998
- 1998-07-17 JP JP10203730A patent/JP2000344773A/ja active Pending

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2016517435A (ja) *	2013-03-15	2016-06-16	カラファーマシューティカルズインコーポレイテッド	メロペネム誘導体及びその使用
JP2019089829A (ja) *	2013-03-15	2019-06-13	カラファーマシューティカルズインコーポレイテッド	メロペネム誘導体及びその製造法
US10392388B2 (en)	2013-03-15	2019-08-27	Kala Pharmaceuticals, Inc.	Meropenem derivatives and uses thereof

Legal Events

Date	Code	Title	Description
2005-07-08	A521	Written amendment	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050707
2005-07-08	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050707
2009-04-02	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090401
2009-08-12	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090811

Publication	Publication Date	Title
US6410525B1 (en)	2002-06-25	Carbapenem derivatives, utilization thereof and intermediate compounds of the same
KR100530478B1 (ko)	2005-11-23	카르바페넴 화합물, 이의 용도 및 이의 중간체 화합물
RU2289582C2 (ru)	2006-12-20	Соединение карбапенема
NO312900B1 (no)	2002-07-15	1-metylkarbapenemderivater, preparat inneholdende dette og anvendelse derav for fremstilling av et medikament
JP2000344772A (ja)	2000-12-12	カルバペネム誘導体、その用途およびその中間体化合物
JPH06192273A (ja)	1994-07-12	カルバペネム−３−カルボン酸エステル誘導体
JPWO1998034936A1 (ja)	2000-07-11	カルバペネム化合物、その用途およびその中間体化合物
MXPA00010753A (en)	2002-06-05	Carbapenem derivatives, utilization thereof and intermediate compounds of the same
HK1035528A (en)	2001-11-30	Carbapenem derivatives, utilization thereof and intermediate compounds of the same
HK1026896B (en)	2004-01-02	Carbapenem compounds, use thereof, and intermediate compounds of the same
MXPA99007344A (en)	2000-01-21	Carbapenem compounds, use thereof, and intermediate compounds of the same
HK1027805A (en)	2001-01-23	Carbapenem compound use thereof and intermediate compound therefor
HK1062679A (en)	2004-11-19	Carbapenem compound
HK1140199B (en)	2014-01-24	Novel carbapenem derivatives